Tirzepatide Reconstitution Calculator

Yes. Tirzepatide is approved in the US for type 2 diabetes as Mounjaro and for chronic weight management as Zepbound; it is also FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity. It is a once-weekly dual GIP/GLP-1 receptor agonist given by subcutaneous injection, not oral or intranasal.

(RCT + community protocol) Standard escalation starts at 2.5 mg once weekly for 4 weeks, then 5 mg weekly; further increases are usually in 2.5 mg steps every 4 weeks to 7.5, 10, 12.5, and 15 mg as tolerated. The 2.5 mg starting dose is for tolerability, not maintenance efficacy.

For obesity, higher doses generally produce more weight loss, with tirzepatide 15 mg ranking among the most effective anti-obesity regimens in network meta-analysis. In community practice, slower titration or holding a dose for 6–8 weeks is common when nausea, constipation, reflux, or fatigue appear (community protocol).

(RCT + real-world) In obesity trials summarized by network meta-analysis, tirzepatide 15 mg produced about 18% mean body-weight reduction versus placebo; in real-world obesity cohorts, 6-month outcomes commonly reach ≥5% loss in most users and ≥10% in many. In a large matched EHR study versus semaglutide, tirzepatide produced greater mean weight reduction over 2 years, 14.7% versus 10.8%, and nearly doubled the proportion achieving ≥15% loss in year 1.

Response is heterogeneous. Women, people without type 2 diabetes, and those who tolerate higher doses tend to lose more weight in retrospective analyses.

(RCT + observational) Tirzepatide is generally stronger for weight loss and at least as strong for glycemic control. Randomized trials show tirzepatide produces larger HbA1c reductions than placebo and substantial weight loss, while comparative evidence versus semaglutide is strongest for weight loss rather than a specific FAQ-level HbA1c claim here.

For cardiovascular outcomes, evidence is stronger and more mature for semaglutide, while tirzepatide appears cardiometabolically favorable but with less definitive event-reduction evidence so far. Meta-analysis found clear MACE reduction for semaglutide, whereas tirzepatide data support cardiovascular safety and probable benefit but remain less conclusive.

(RCT + observational) Gastrointestinal effects dominate: nausea, constipation, diarrhea, vomiting, abdominal discomfort, and reduced appetite. In a 24-week prospective observational study of adults with psoriasis and obesity receiving low-dose tirzepatide, constipation occurred in 25%, nausea in 12%, and diarrhea in 4%.

Risk mitigation is practical: eat smaller meals, reduce dietary fat at dose-escalation, stop when comfortably full, prioritize fluids, and delay upward titration if symptoms last more than a few days (practitioner consensus). Severe constipation, persistent vomiting, progressive abdominal distension, or inability to tolerate liquids should prompt dose hold and evaluation because GLP-1-based therapies are associated with a modestly higher risk of severe motility-related GI events than SGLT2 inhibitors, although absolute risk is low.

(Observational) Possibly. Pharmacovigilance and retrospective studies suggest a signal for alopecia/hair loss with GLP-1-based therapies, with tirzepatide and semaglutide among the stronger signals, but causality is not proven. The pattern is thought to be mainly telogen effluvium triggered by rapid weight loss, calorie restriction, and micronutrient shortfalls rather than direct follicle toxicity.

Risk is probably higher with rapid loss phases. Practical prevention is adequate protein intake, resistance training, and monitoring iron and other micronutrients if intake is low or weight loss is very fast (practitioner consensus).

(Mechanistic + observational + practitioner consensus) Do not use during pregnancy (practitioner consensus). Tirzepatide delays gastric emptying and can reduce the effectiveness of oral contraceptives, especially during initiation and dose escalation; backup non-oral or barrier contraception is commonly advised for 4 weeks after starting and 4 weeks after each dose increase.

If trying to conceive, most practitioners stop tirzepatide in advance and manage rebound appetite and weight regain with structured diet, activity, and close follow-up (practitioner consensus). Abrupt discontinuation near conception may allow rapid weight rebound. Abrupt discontinuation close to conception was associated with higher gestational diabetes risk in one observational study.

(RCT + observational) Long term if it remains effective and tolerated. Obesity behaves like a chronic relapsing disease, and discontinuation of GLP-1-based therapy is commonly followed by weight regain; real-world 1-year persistence for weight-loss-indicated tirzepatide was about 64%.

A practical reassessment point is 12–24 weeks after reaching an effective maintenance dose. If weight loss is clearly inadequate, adherence is poor, or adverse effects remain limiting despite slower titration, switching strategy is reasonable (practitioner consensus).

(RCT + case report + pharmacovigilance) Use extra caution in people with severe baseline constipation, prior bowel obstruction, pancreatitis history, active eating disorder, insulin-treated diabetes with major dose changes, or very low calorie intake. Ketoacidosis-spectrum events, especially starvation ketosis, have been reported post-marketing and may be more likely with marked appetite suppression, vomiting, peri-operative fasting, or overly aggressive insulin reduction.

Older adults did not show major safety differences versus younger adults in pooled post hoc analyses, but they still need closer monitoring for dehydration, frailty, and lean-mass loss. If symptoms include persistent upper abdominal pain, repeated vomiting, fruity breath, rapid breathing, or confusion, urgent evaluation is warranted.